Cervera Grau J M, Esquerdo Galiana G, Belso Candela A, Llorca Ferrándiz C, Juárez Marroquí A, Maciá Escalante S
Oncology Department, Hospital General de Elda, Elda, Alicante, Spain.
Clin Transl Oncol. 2008 May;10(5):298-9. doi: 10.1007/s12094-008-0201-1.
Rituximab is a treatment option to non-Hodg kin's diffuse large B-cell lymphoma (NHDLBCL) in advanced stage and comorbility. It is known the cardiotoxicity effect of this drug, but there is no previous report describing a complete atrioventricular block (CAVB) secundary to treatment with Rituximab. We present an elderly woman treated with monotherapy with Rituximab who experienced a CAVB after administration of the fifth dose of this drug.
利妥昔单抗是晚期合并症非霍奇金弥漫性大B细胞淋巴瘤（NHDLBCL）的一种治疗选择。已知该药物具有心脏毒性作用，但此前尚无关于利妥昔单抗治疗继发完全性房室传导阻滞（CAVB）的报道。我们报告了一名接受利妥昔单抗单药治疗的老年女性，在使用该药物第五剂后出现了CAVB。
